Together, these results demonstrate that a local anti-inflammatory treatment improved intestinal permeability and visceral hypersensitivity in a preclinical, spontaneous model of DGBI. Moreover, it supports a role for intestinal inflammation in the intestinal barrier defect and symptoms, further paving the way for additional evaluation of anti-inflammatory treatments, including budesonide, in DGBI.
Accarie et al. (Thu,) studied this question.